| Literature DB >> 36081554 |
Yujue Wang1, Tian'an Jiang1,2,3, Liting Xie1,2, Huiyang Wang1,2, Jing Zhao1, Lei Xu1, Chengyu Fang1.
Abstract
Pulsed field ablation can increase membrane permeability and is an emerging non-thermal ablation. While ablating tumor tissues, electrical pulses not only act on the membrane structure of cells to cause irreversible electroporation, but also convert tumors into an immune active state, increase the permeability of microvessels, inhibit the proliferation of pathological blood vessels, and soften the extracellular matrix thereby inhibiting infiltrative tumor growth. Electrical pulses can alter the tumor microenvironment, making the inhibitory effect on the tumor not limited to short-term killing, but mobilizing the collective immune system to inhibit tumor growth and invasion together.Entities:
Keywords: immunogenic cell death; irreversible electroporation; microenvironment; nanosecond pulsed electric fields; pulsed field ablation
Year: 2022 PMID: 36081554 PMCID: PMC9447365 DOI: 10.3389/fonc.2022.899722
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 5.738
Figure 1Effect of pulsed field ablation on cell signal pathway.
Effects of pulsed field ablation on tumor microenvironment.
| Factors | Intervention | Parameters | Mode of action |
| Type of tumor | ||||
|---|---|---|---|---|---|---|---|---|---|
| V | EFS | PW | PRF | N | |||||
| DAMP | |||||||||
| 1.CRT | IRE | 1000 | – | 100 | – | 80 | 24h: Increased by about 6.1 times. |
| The Lewis lung carcinoma (LLC, CRL-1642) ( |
| 2.ATP | IRE | 200 | – | 100 | 1 | 20 | Within 30min: No significant difference. |
| KRAS* ( |
| 960 | – | 100 | 1 | 20 | Within 30min: Increased |
| KRAS* ( | ||
| 1000 | – | 100 | – | 80 | 24h: Increased by about 1.6 times. |
| The Lewis lung carcinoma (LLC, CRL-1642) ( | ||
| 500 | – | 100 | 1 | 20 | Increased |
| KPC ( | ||
| nsPEF | – | 7000 | 0.2 | 10 | – | No significant difference (CT26) |
| EL-4 lymphoma; CT26 colon carcinoma cells ( | |
| 3. HMGB1 | IRE | 200 | – | 100 | 1 | 20 | Within 30min: No significant difference at 200V, increased at 960V. |
| KRAS* ( |
| 200 | – | 100 | 1 | 20 | Within 30min: No significant difference at 200V, increased at 960V. |
| B16F10 ( | ||
| 500–1500 | – | 100 | – | 8 | 24h: Increased in a strength-dependent manner. |
| Panc-1, Bxpc-3, Pan02 ( | ||
| 1000 | – | 100 | – | 8 | 24h: Increased by about 7.3 times. |
| The Lewis lung carcinoma ( | ||
| nsPEF | – | 7000 | 0.2 | 10 | – | Increased |
| EL-4 lymphoma; CT26 colon carcinoma cells ( | |
| 4.HSP70 | IRE | 500–1500 | – | 100 | – | 24 | 24h: Increased in a strength-dependent manner |
| Panc-1, Bxpc-3, Pan02 ( |
| 5.Calreticulin | IRE | 500–1500 | – | 100 | – | 24 | 24h: Increased in a strength-dependent manner |
| Panc-1, Bxpc-3, Pan02 ( |
| Phagocytes | |||||||||
| 1.Macrophages | IRE | 1000 | – | 100 | 1 | 80 | Day 7: M1 polarized and Increased in a strength-dependent manner |
| PC ( |
| 2.DC | IRE | 1200 | – | 100 | 1 | 99 | Day 9: No significant difference. |
| PC ( |
| 3.NK | IRE | – | – | – | – | – | Day 3: decreased |
| PC ( |
| nsPEF | 20000 | – | 0.3 | 4 | 1000 | Day 8: increased |
| HCC ( | |
|
| |||||||||
| IL-1a | IRE | 3000 | – | 70 | – | 90 | 2 h: increased |
| HCC ( |
| IL-1b | IRE | 3000 | – | 70 | – | 90 | 2 h: increased |
| HCC ( |
| nsPEF | 30000 | – | 0.3 | – | 400 | Day 7: increased |
| PC ( | |
| IL-2 | IRE | 3000 | – | 70 | – | 90 | 2 h: increased |
| HCC ( |
| – | – | – | – | – | Day 7: increased (more than Day 3 and preOP) |
| PC ( | ||
| nsPEF | 20000 | – | 0.3 | 4 | 1000 | Day 8: increased |
| HCC ( | |
| IL-5 | nsPEF | 20000 | – | 0.3 | 4 | 1000 | Day 8: increased |
| HCC ( |
| IL-6 | IRE | – | – | – | – | – | Day 3: increased |
| PC ( |
| nsPEF | 20000 | – | 0.3 | 4 | 1000 | Day 8: increased |
| HCC ( | |
| 30000 | – | 0.3 | – | 400 | Day 3: decreased |
| PC ( | ||
| IL-10 | IRE | – | – | – | – | – | Day 3: increased |
| PC ( |
| 3000 | – | 70 | – | 90 | 2 h: increased |
| HCC ( | ||
| nsPEF | 20000 | – | 0.3 | 4 | 1000 | Day 8: increased |
| HCC ( | |
| IL-12 | IRE | 3000 | – | 70 | – | 90 | 2 h: increased |
| HCC ( |
| IL-17A | nsPEF | 20000 | – | 0.3 | 4 | 1000 | Day 8: increased |
| HCC ( |
| IL-17F | nsPEF | 20000 | – | 0.3 | 4 | 1000 | Day 8: increased |
| HCC ( |
| IL-21 | nsPEF | 20000 | – | 0.3 | 4 | 1000 | Day 8: increased |
| HCC ( |
| IL-22 | nsPEF | 20000 | – | 0.3 | 4 | 1000 | Day 8: increased |
| HCC ( |
| IFN-γ | IRE | – | – | – | – | – | No significant difference |
| PC ( |
| 3000 | – | 70 | – | 90 | 2 h: increased |
| HCC ( | ||
| nsPEF | 20000 | – | 0.3 | 4 | 1000 | Day 8: increased |
| HCC ( | |
| TNF-α | IRE | 3000 | – | 70 | – | 90 | 2 h: increased |
| HCC ( |
| nsPEF | 30000 | – | 0.3 | – | 400 | Day 7: increased |
| PC ( | |
| 20000 | – | 0.3 | 4 | 1000 | Day 8: increased |
| HCC ( | ||
| GM-CSF | IRE | 3000 | – | 70 | – | 90 | 2 h: increased |
| HCC ( |
| C3 | IRE | – | – | – | – | – | Day 3: decreased |
| PC ( |
| C4 | IRE | – | – | – | – | – | Day 3: decreased |
| PC ( |
|
| |||||||||
| 1.Treg | IRE | – | – | – | – | – | Day 3: increased |
| PC ( |
| – | 1500 | 90 | – | – | Week 2: decreased |
| PC ( | ||
| 1200 | – | 100 | 1 | 99 | Day 9: No significant difference |
| PC ( | ||
| nsPEF | – | 30000 | 0.3 | – | 400 | Day 3: slightly increased |
| PC ( | |
| – | 30000 | 0.1 | 1 | 200 | Day 4: decreased |
| Malignant melanoma ( | ||
| H-FIRE | – | 2500 | 100 | – | – | Day 2: increased |
| 4T1 mammary tumor ( | |
| 2.TAM | H-FIRE | – | 2500 | 100 | – | – | Day 2: decreased |
| 4T1 mammary tumor ( |
| 3.MDSC | IRE | – | 1500 | 90 | – | – | Day 14: eMDSC decreased |
| PC ( |
| nsPEF | – | 30000 | 0.3 | – | 400 | Day 3&7: nMDSC & mMDSC decreased |
| PC ( | |
| – | 30000 | 0.1 | 1 | 200 | Day 4: decreased |
| Malignant melanoma ( | ||
| H-FIRE | – | 2500 | 100 | – | – | Day 2: pMDSC decreased |
| 4T1 mammary tumor ( | |
| 4.TAN | H-FIRE | – | 2500 | 100 | – | – | Day 2: decreased |
| 4T1 mammary tumor ( |
| Adaptive immunity | |||||||||
| CD 4+ T cell | IRE | – | – | – | – | – | Week 2: increased |
| PC ( |
| 1200 | – | 100 | 1 | 99 | Day 9: No significant difference |
| PC ( | ||
| – | – | – | – | – | Day 3: decreased |
| PC ( | ||
| nsPEF | – | 20000 | 300 | 4 | 1000 | Day 8: increased |
| HCC ( | |
| CD 8+ T cell | IRE | 1200 | – | 100 | 1 | 99 | Day 9: increased |
| PC ( |
| – | – | – | – | – | Day 3: decreased |
| PC ( | ||
| 1000 | – | 100 | – | 90 | increased |
| HCC ( | ||
| nsPEF | – | 20000 | 300 | 4 | 1000 | Day 8: increased |
| HCC ( | |
| B cell | IRE | 1200 | – | 100 | 1 | 99 | Day 9: No significant difference |
| PC ( |
| nsPEF | – | 20000 | 300 | 4 | 1000 | Day 8: increased |
| HCC ( | |
| IgA | IRE | – | – | – | – | – | Day 3&7: No significant difference |
| PC ( |
| IgG | IRE | – | – | – | – | – | Day 3: decreased |
| PC ( |
| IgM | IRE | – | – | – | – | – | Day 3&7: No significant difference |
| PC ( |
|
| |||||||||
| VEGF | nsPEF | – | 20000 | 0.1 | – | 100 | 1h: decrease |
| HCC ( |
| CD31 | IRE | 1000 | – | 100 | 1 | 80 | Day 7: increased |
| PC ( |
| 1200 | – | 100 | 1 | 99 | Day 4: transient increase |
| PC ( | ||
| CD34 | nsPEF | – | 20000 | 0.1 | – | 100 | 1h: decrease |
| Hep-3B HCC ( |
| FITC-conjugated dextran | IRE | 1200 | – | 100 | 1 | 99 | Day 4: increased |
| PC ( |
| FAPα | IRE | 1200 | – | 100 | 1 | 99 | Day 4: decreased |
| PC ( |
| HABP1 | IRE | 1200 | – | 100 | 1 | 99 | Day 6: decreased |
| PC ( |
| nsPEF | 1000 | – | 100 | 1 | 80 | Day 3: decreased |
| PC ( | |
| LOX | IRE | 1000 | – | 100 | 1 | 80 | Day 3: decreased |
| PC ( |
| 1200 | – | 100 | 1 | 99 | Day 6: decreased |
| PC ( | ||
| α- SMA | IRE | 1200 | – | 100 | 1 | 99 | Day 6: No significant difference |
| PC ( |
| nsPEF | 1000 | – | 100 | 1 | 80 | Day 3&7: No significant difference |
| PC ( | |
| MMP | nsPEF | 20000–60000 | 100 | – | 100 | 1 h: decrease |
| HCC ( | |
| CA-IX | IRE | 1200 | – | 100 | 1 | 99 | Day 6: decreased |
| PC ( |
| HIF-1α | IRE | 1200 | – | 100 | 1 | 99 | Day 6: decreased |
| PC ( |
V, Voltage (V); EFS, electric field intensity (V/cm); PW, Pulse width (µs); PRF, Pulse repetition frequency (Hz); N, Number of pulses; min, minutes; h, hour; HCC, hepatic cancer; PC, pancreatic cancer; RE, reversible electroporation; IRE, irreversible elecrtroporation; nsPEF, nanosecond pulsed electric fields; H-FIRE, High-frequency irreversible electroporation.